A breakthrough in the treatment of breast cancer
An innovative treatment developed by Hospital Clínic de Barcelona is showing promising results in the fight against advanced breast cancer. This new treatment, based on a combination of drugs, has been shown to almost halve the progression of the disease in patients with advanced breast cancer, according to the results of a clinical trial presented at a congress of the American Association of Medical Oncology.
An alternative to chemotherapy
Unlike conventional treatments that include chemotherapy, this new treatment uses a combination of hormone therapy, trastuzumab and palociclib. This combination has been shown to be more effective and better tolerated by patients with advanced, metastatic breast cancer of the ER+/HER2+ type. In addition, the results of the clinical trial show that the treatment is safe and promising.
Benefits for patients
The results of the study indicate that patients with tumors that express genes related to the estrogen receptor (ER+) derive significant benefits from this alternative therapy. The risk of disease progression is almost halved compared to conventional treatment that includes chemotherapy and trastuzumab. In addition, the median time to disease progression is longer with the experimental treatment.
A step towards personalization of treatment
This study is an important step towards personalizing the treatment of advanced breast cancer. Molecular screening of HER2+/ER+ breast cancer patients allows for new combinations of treatments that do not include chemotherapy. This not only improves the effectiveness of the treatment, but also improves the quality of life of the patients.
A promising future
This new treatment represents a significant advance in the fight against advanced breast cancer. With promising clinical trial results, this alternative therapy offers new hope for patients. Researchers continue to work to improve and expand this treatment, with the goal of providing a more effective and safer option for patients with advanced breast cancer.